FDA Approves GLP-1 Pill for Primary, Secondary Cardiovascular Protection

(MedPage Today) — The FDA approved oral semaglutide (Rybelsus) to prevent major adverse cardiovascular events (MACE) in high-risk patients with diabetes, whether or not they’ve had such an event already, Novo Nordisk announced.
Semaglutide 7…